As a result, T-DXd was approved for patients with unresectable or metastatic HER2-low breast cancer who have received one prior line of chemotherapy in the metastatic setting or developed disease recurrence during or within six months of completing adjuvant chemotherapy. Here, ERBB2 is linked to breast cancer.